Abstract
Purpose: GD2 is highly expressed in neuroblastoma (NB) and specifically recognized by antibody ch14.18/CHO. Immunotherapy with bolus infusion of ch14.18 in combination with cytokines effectively prolonged survival associated with substancial toxicity. Therefore, we piloted a treatment using continuous infusion of ch14.18 and report first results of clinical responses.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
